CALIWAY BIOPHARMACEUTICALS CO., LTD.
Update：2025/12/24
Industries
Main Industry
Health Care
Main Product/Service
Caliway’s pipeline includes: CBL‑514, an injectable drug targeting localized fat reduction, cellulite, and Dercum’s disease through adipocyte apoptosis; CBA‑539, a long‑acting injectable for hyperpigmentation and skin aging; and CBF‑520, a chemical entity
Founded Year
2012
Unified Business No.
53942917
Status
Active
Number of Employees
0
Total Paid-in
Capital
776,938,930 (NT$)
Location of Company
Taiwan
, New Taipei City
Exit Status
Emerging Stock Exchange(2025)、Listing(2024)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, Ministry of Economic Affairs.
Exclusive content for members
Members-only content. Please log in to access.
Introduction
Caliway Biopharmaceuticals Co., Ltd. is a clinical‑stage biotech company headquartered in New Taipei City, Taiwan, dedicated to discovering novel small‑molecule therapeutics. The company focuses on aesthetic medicine and chronic inflammatory diseases, aim
